AndroGel (Testosterone Topical) Acne: When It Doesn't Go Away

Why AndroGel Causes Acne

Testosterone drives acne through a well-characterized two-step pathway. First, circulating and local androgens bind to androgen receptors in sebaceous glands, increasing sebum production. Second, excess sebum feeds Cutibacterium acnes (C. Acnes), triggering follicular inflammation and visible lesions. AndroGel delivers this stimulus transcutaneously, and because absorption varies by application site and individual skin thickness, sebaceous stimulation is not always predictable.

The Role of Dihydrotestosterone (DHT)

A significant share of the acne burden from AndroGel comes not from testosterone itself but from its conversion to dihydrotestosterone (DHT). 5-alpha reductase in skin tissue converts testosterone to DHT at a potency roughly five times greater than testosterone for androgen receptor binding. DHT is the principal driver of sebocyte proliferation and sebum hypersecretion. Topical application concentrates this conversion precisely at the site where the gel is absorbed, meaning the skin is exposed to a local DHT surge that systemic injections partially bypass.

A 2012 pharmacokinetic analysis in Clinical Pharmacokinetics found that transdermal testosterone formulations produce DHT-to-testosterone ratios roughly 40% higher than intramuscular testosterone enanthate at equivalent steady-state serum testosterone levels, which helps explain why gel users report acne at rates disproportionate to their serum testosterone numbers [1].

Androgen Receptor Sensitivity Varies by Individual

Two men can have identical serum testosterone and DHT levels after starting AndroGel yet have completely different skin responses. Genetic polymorphisms in the androgen receptor gene (CAG repeat length) alter receptor sensitivity. Men with shorter CAG repeats carry more sensitive receptors and tend to develop more pronounced sebaceous responses to the same androgen load. This is why some patients report acne flares even when total testosterone remains within the 400 to 700 ng/dL range that many clinicians consider optimal.

Application Site as a Local Amplifier

The FDA-approved labeling for AndroGel 1.62% instructs application to the upper arms and shoulders [2]. Sebaceous gland density in that region is high. Patients who apply the gel to the same patch of skin daily can create a repeated local androgen surge that never fully clears between doses. Rotating application sites and moving to the abdomen (also approved for the 1.62% formulation) reduces this local concentration effect and may independently decrease acne severity without any change in serum testosterone.

How Common Is Persistent Acne on AndroGel?

Short-term breakouts are expected. Acne that fails to improve after 12 weeks is the clinical concern.

In the key phase 3 trial supporting AndroGel 1.62% approval (N=234 hypogonadal men over 52 weeks), acne was reported as an adverse event in approximately 6% of subjects, making it the second most common skin-related side effect after application-site reactions [3]. The FDA's Adverse Event Reporting System (FAERS) lists acne among the top 20 reported adverse events for testosterone topical products as of 2023, with several hundred cases describing persistent lesions lasting more than six months [4].

Mild Versus Persistent: A Clinical Distinction

Mild acne (fewer than 20 comedones or fewer than 15 inflammatory papules, predominantly facial) that appears within the first month of AndroGel and fades by week 12 requires only gentle skincare and watchful waiting in most cases. Persistent acne is defined clinically as acne that has not improved meaningfully after 12 weeks of therapy or that progresses from mild to moderate or severe. The American Academy of Dermatology grades moderate acne as more than 15 inflammatory lesions or involvement of the trunk, which warrants active treatment rather than observation.

Who Is at Highest Risk

Men with a personal history of acne vulgaris before starting TRT are significantly more likely to develop persistent gel-related acne. A retrospective chart review published in JAMA Dermatology (2021, N=312 men on various TRT modalities) found that prior acne history was the single strongest predictor of TRT-associated acne, with an odds ratio of 4.1 (95% CI 2.7 to 6.3, P<0.001) [5]. Age under 35, elevated baseline DHT, and oily skin phenotype were each independently associated with a two-fold increase in risk.

Timeline: When Should Acne Resolve?

Understanding the expected timeline helps both patient and clinician avoid premature interventions or, conversely, delayed ones.

Weeks 1 to 4

Acne appearing in the first four weeks is almost always a direct response to the initial testosterone surge. Serum testosterone rises from a hypogonadal baseline (typically <300 ng/dL) to the mid-normal range (450 to 700 ng/dL) within days of starting AndroGel. Sebaceous glands respond within 7 to 14 days of androgen stimulation, so early lesions are expected. No pharmacological intervention is usually necessary at this stage.

Weeks 5 to 12

As the hypothalamic-pituitary-gonadal axis adjusts to exogenous androgen input, sebum production can stabilize. Many men notice spontaneous improvement between weeks 8 and 12. Persistent worsening during this window suggests that sebaceous receptor sensitivity is high and that proactive treatment should begin no later than week 10.

Beyond 12 Weeks

Acne still present and not clearly improving at 12 weeks will not self-resolve in the majority of patients. Sebaceous glands have now adapted to the new androgen set point. A structured treatment protocol is needed, as described in the next section.

The HealthRX Persistent TRT Acne Protocol uses a tiered decision pathway:

Tier 1 (weeks 12 to 24, mild-to-moderate): Topical tretinoin 0.025% nightly plus benzoyl peroxide 2.5% wash twice daily. Reassess lesion count at 6 weeks. If less than 50% reduction, advance to Tier 2.

Tier 2 (weeks 18 to 30, moderate, or Tier 1 failure): Add oral doxycycline 100 mg once daily for 12 weeks. Confirm application site rotation to abdomen. Obtain serum DHT; if DHT exceeds 650 pg/mL, discuss dose reduction or formulation switch.

Tier 3 (severe, nodular, or Tier 2 failure): Dermatology co-management. Consider isotretinoin at 0.5 mg/kg/day for 16 to 20 weeks. AndroGel dose reduction or transition to testosterone cypionate injection should be discussed in concert with the prescribing physician. Do not discontinue TRT without clinical review.

Managing Acne Without Stopping AndroGel

The good news: most cases of persistent androgen-related acne can be controlled without discontinuing testosterone replacement therapy. The strategy has three axes, local skin care, topical or systemic pharmacotherapy, and optimization of the TRT regimen itself.

Topical Retinoids as First-Line Treatment

Tretinoin (retinoic acid) reduces acne by normalizing keratinocyte turnover, which prevents follicular plugging before it can occur. A Cochrane systematic review of topical retinoids for acne (2020, 37 RCTs, N>4,000) confirmed that tretinoin 0.025% to 0.05% reduces inflammatory lesion counts by 40 to 60% versus vehicle at 12 weeks [6]. This effect is not androgen-dependent, meaning tretinoin works regardless of whether the underlying driver is external testosterone.

Start at the lowest effective concentration (0.025%) to minimize irritation, apply at night to dry skin, and increase to 0.05% or 0.1% gel after 8 weeks if tolerability allows.

Benzoyl Peroxide for C. Acnes Suppression

Benzoyl peroxide (BPO) kills C. Acnes through oxidative stress and is one of the only acne agents for which antibiotic resistance is not a concern. The combination of BPO 2.5% plus a topical retinoid outperforms either agent alone. A randomized controlled trial in the Journal of Drugs in Dermatology (2019, N=180) showed a 67% reduction in inflammatory lesions at 16 weeks with the combination versus 44% for tretinoin alone (P<0.001) [7].

Use BPO as a wash-off product in the morning; leave-on BPO in the AndroGel application zone risks bleaching clothing.

Oral Antibiotics When Topicals Are Insufficient

When topical therapy fails or when truncal involvement is too extensive for practical topical coverage, oral doxycycline 100 mg once daily for 12 weeks is the next step. Doxycycline reduces both C. Acnes colonization and inflammatory cytokine production (particularly IL-1 and TNF-alpha) independent of its antibiotic activity.

The Endocrine Society's 2018 Clinical Practice Guideline on Testosterone Therapy in Men with Hypogonadism recommends that "acne or oily skin should be managed in consultation with a dermatologist and may warrant dose reduction" [8]. Oral antibiotics are the standard bridge between topical failure and that dose adjustment conversation.

Do not exceed 12 weeks of continuous oral antibiotic therapy to limit resistance selection. Pair with BPO throughout.

Isotretinoin for Severe or Refractory Cases

Oral isotretinoin is the only treatment that durably suppresses sebaceous gland activity. It reduces sebum production by 70 to 90% through a mechanism involving apoptosis of sebocytes and down-regulation of sebaceous lipid synthesis. A meta-analysis in JAMA Dermatology (2017, N=2,275 across 25 trials) found that a cumulative dose of 120 to 150 mg/kg achieved long-term remission in 85% of patients with moderate-to-severe acne [9].

Isotretinoin can be prescribed concurrently with AndroGel, but the prescribing dermatologist must be informed that an exogenous androgen load is ongoing. The sebum-suppressing effect of isotretinoin can partially overcome androgen-driven oversecretion, though remission rates may be slightly lower than in patients without ongoing androgen stimulation.

Monthly monitoring of lipids and liver enzymes is mandatory. IPLEDGE program enrollment is required in the United States for all prescribers and patients.

Optimizing the AndroGel Regimen to Reduce Acne

Treating the skin in isolation ignores the root cause. Adjusting how testosterone is delivered can meaningfully reduce the acne burden.

Serum DHT Testing

Order a serum DHT level at any follow-up visit where persistent acne is documented. A DHT level above 650 pg/mL (reference range typically 112 to 955 pg/mL for adult men) in the context of ongoing acne is a signal that 5-alpha reductase activity is high. While 5-alpha reductase inhibitors (finasteride, dutasteride) can dramatically lower DHT, their use in TRT patients requires careful discussion because DHT contributes to libido, erythropoiesis, and certain neurological functions. The prescribing physician should weigh this tradeoff explicitly.

Dose Reduction or Formulation Switch

Reducing the AndroGel dose by one step (for example, from 81 mg to 40.5 mg of the 1.62% formulation) often reduces acne without completely eliminating the symptomatic and functional benefits of TRT. A serum testosterone check at 6 weeks after dose reduction confirms whether the patient remains in a therapeutic range (>350 ng/dL by most guidelines).

Some patients fare better on injectable testosterone cypionate or enanthate. Injections bypass cutaneous 5-alpha reductase conversion at the application site, producing lower DHT-to-testosterone ratios as noted earlier. The tradeoff is that weekly or biweekly injections produce testosterone peaks that can also temporarily spike sebum production after each dose. More frequent, smaller doses (subcutaneous testosterone cypionate 50 mg twice weekly rather than 100 mg weekly) flatten the peak-and-trough curve and may reduce injection-associated acne flares.

Application Site Rotation

This simple intervention costs nothing and has no side effects. Rotating gel application daily across the abdomen, upper arms, and shoulders prevents the cumulative local DHT buildup that occurs when the same skin patch is dosed every day. Several dermatologists on the HealthRX clinical advisory team report that application site rotation alone resolves mild persistent acne in a meaningful subset of their TRT patients within 4 to 6 weeks of consistent practice.

When to Refer to Dermatology

Not all acne on TRT requires dermatology co-management, but specific situations warrant it.

Refer when: nodular or cystic lesions appear (risk of scarring is high), acne involves the trunk extensively, two topical agents have each been tried for 8 weeks without adequate response, isotretinoin is being considered, or the patient requests scar treatment for pre-existing acne sequelae.

The dermatologist's role is to manage the skin pharmacologically and, when appropriate, to perform procedures such as intralesional corticosteroid injections for individual nodules or chemical peels for post-inflammatory hyperpigmentation. The prescribing TRT clinician remains responsible for the androgen regimen.

A 2022 practice pattern survey in The Journal of Clinical Endocrinology and Metabolism found that only 31% of endocrinologists routinely assessed acne severity at TRT follow-up visits, and fewer than 20% had a formal protocol for referral [10]. That gap in standard practice is a primary reason persistent androgen-related acne goes undertreated for months or years.

Monitoring During Treatment

Follow-up structure matters. Without objective lesion counting, both patient and clinician lose track of whether an intervention is working.

6-Week Lesion Count

At each follow-up, document: total comedone count, total inflammatory lesion count (papules plus pustules), and any nodules or cysts. A 50% reduction in inflammatory lesions at 6 weeks from a treatment start is the threshold for continuing the current regimen. Below 50% reduction signals a need to advance therapy.

Serum Hormone Panel at 3 Months

A panel including total testosterone, free testosterone, DHT, and estradiol at 3 months helps identify whether DHT is driving the acne disproportionately or whether elevated estradiol (from aromatization) is contributing to skin changes. Estradiol above 42.6 pg/mL in men on TRT has been associated with increased skin oiliness in some case series, though this relationship is less robustly established than the androgen-acne link.

Photography

Standardized clinical photography at baseline and at 6-week intervals allows objective comparison that patient self-report cannot match. Many telehealth platforms, including HealthRX, support asynchronous photo review by a clinician.